Does Autolus Therapeutics plc (AUTL) Have Any Gas After Today’s Big Increase?

The stock of Autolus Therapeutics plc (NASDAQ:AUTL) is a huge mover today! The stock increased 8.71% or $1.08 during the last trading session, reaching $13.48. About 267,749 shares traded. Autolus Therapeutics plc (NASDAQ:AUTL) has declined 34.88% since September 13, 2018 and is downtrending. It has underperformed by 34.88% the S&P500.
The move comes after 5 months positive chart setup for the $606.36 million company. It was reported on Sep, 13 by We have $13.88 PT which if reached, will make NASDAQ:AUTL worth $18.19M more.

Analysts await Autolus Therapeutics plc (NASDAQ:AUTL) to report earnings on February, 24. After $-0.65 actual EPS reported by Autolus Therapeutics plc for the previous quarter, Wall Street now forecasts 30.77 % negative EPS growth.

More notable recent Autolus Therapeutics plc (NASDAQ:AUTL) news were published by: which released: “46 Stocks Moving In Friday’s Mid-Day Session – Benzinga” on September 06, 2019, also with their article: “Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia – GlobeNewswire” published on April 23, 2019, published: “64 Biggest Movers From Friday – Benzinga” on September 09, 2019. More interesting news about Autolus Therapeutics plc (NASDAQ:AUTL) were released by: and their article: “Autolus Announces Proposed Public Offering in the United States – GlobeNewswire” published on April 08, 2019 as well as‘s news article titled: “AUTL, CRWD, DOCU and ENDP among midday movers – Seeking Alpha” with publication date: September 06, 2019.

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. The company has market cap of $606.36 million. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.